Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...

HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: DRUG), a ...

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...

Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued ...

The poster is available on www.brightmindsbio.com. BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the ...

as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists. “The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the ...